BioNxt Solutions Inc. (CVE:BNXT)

BRIEF

published on 04/28/2026 at 09:10, 3 days 11 hours ago

BioNxt Explores Psychedelic Drug Delivery Advances

Drug Delivery Technology Mental Health Treatments BioNxt Solutions Regulatory Developments Psychedelic Therapeutics
PRESS RELEASE

published on 04/28/2026 at 09:05, 3 days 11 hours ago

BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum
BioNxt Solutions Inc. is exploring applying its drug delivery tech to psychedelic therapeutics amid global momentum. Market opportunity in mental health treatments highlighted

BioNxt Solutions Inc. Mental Health Disorders Drug Delivery Technologies Psychedelic Therapeutics Advanced Drug Delivery
BRIEF

published on 04/14/2026 at 09:10, 17 days 11 hours ago

BioNxt Commences GMP Manufacturing for Multiple Sclerosis Treatment

Clinical Trials Multiple Sclerosis GMP Manufacturing BioNxt Solutions Sublingual Cladribine
PRESS RELEASE

published on 04/14/2026 at 09:05, 17 days 11 hours ago

BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)
BioNxt announces successful completion of GMP manufacturing for sublingual Cladribine oral thin film, advancing to clinical-stage execution. Company aims to treat MS and neurodegenerative diseases

GMP Manufacturing Sublingual Cladribine MS Treatment BioNxt Clinical-stage Execution
BRIEF

published on 04/07/2026 at 09:10, 24 days 11 hours ago

BioNxt Solutions Secures European Patent for Sublingual Cladribine Platform

Drug Delivery European Patent BioNxt Solutions Sublingual Cladribine ODF Platform
PRESS RELEASE

published on 04/07/2026 at 09:05, 24 days 11 hours ago

BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
BioNxt Solutions Inc. secures Unitary Patent registration for sublingual cladribine oral thin film technology in Europe, enhancing commercialization prospects and partnership opportunities

BioNxt Solutions Inc. Drug Delivery European Patent Sublingual Cladribine Unitary Patent
BRIEF

published on 03/30/2026 at 09:10, 1 month 2 days ago

BioNxt Progresses with Semaglutide ODF Program

Semaglutide Peptide Therapeutics BioNxt GLP-1 Platform ODF Strategy
PRESS RELEASE

published on 03/30/2026 at 09:05, 1 month 2 days ago

BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
BioNxt Solutions Inc. provides update on semaglutide ODF program and platform strategy. Focus on GLP-1 receptor agonists and peptide-based therapeutics. Potential market growth and commercial outlook discussed

GLP-1 Receptor Agonists BioNxt Solutions Market Opportunity Peptide-based Therapeutics Semaglutide ODF Program
BRIEF

published on 03/24/2026 at 10:15, 1 month 8 days ago

BioNxt Advances Commercial Strategy with Global Patents and U.S. Fast Track

Commercialization Pharmaceutical Partnerships BioNxt Solutions Sublingual Drug Delivery Global Patent
PRESS RELEASE

published on 03/24/2026 at 10:10, 1 month 8 days ago

BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform
BioNxt Solutions Inc. announces major advancement in commercialization strategy with global patent portfolio expansion for sublingual drug delivery platform. Strong intellectual property and transitioning to commercialization phase

BioNxt Solutions Inc. Intellectual Property Commercialization Drug Delivery Systems Global Patents

Published on 05/01/2026 at 18:00, 2 hours 25 minutes ago

Star Copper to Present at the Emerging Growth Conference on May 7, 2026
Published on 05/01/2026 at 15:35, 4 hours 50 minutes ago

LNG Energy Group Announces Partial Revocation of Cease Trade Order and Proposed Private Placement
Published on 05/01/2026 at 14:00, 6 hours 25 minutes ago

CCL Industries Closing of ALT Technologies Acquisition
Published on 05/01/2026 at 14:00, 6 hours 25 minutes ago

Datavault AI and CyberCatch Announce Signing of Binding Letter of Intent for Datavault AI to Acquire CyberCatch to Accelerate AI-Driven, Quantum-Resistant Cyber Risk Mitigation Solutions
Published on 05/01/2026 at 13:01, 7 hours 24 minutes ago

BeMetals Announces Resumption of Trading on TSX Venture Exchange and Effective Date of Share Consolidation

View all ACCESSWIRE

Published on 05/01/2026 at 19:23, 1 hour 2 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/01/2026 at 18:40, 1 hour 45 minutes ago

Holding(s) in Company
Published on 05/01/2026 at 17:47, 2 hours 38 minutes ago

Key Figures 30.04.2026
Published on 05/01/2026 at 17:45, 2 hours 40 minutes ago

Burkhalter Group acquires Progressio Holding GmbH and anplaq ag, Tamins (GR)
Published on 05/01/2026 at 17:21, 3 hours 4 minutes ago

Fuller, Smith & Turner PLC: Total Voting Rights and Treasury Shares

View all EQS

Published on 04/30/2026 at 20:00, 1 day ago

AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 1 day 1 hour ago

AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 1 day 1 hour ago

Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 1 day 2 hours ago

Minutes of the Combined General Meeting held on April 30, 2026
Published on 04/30/2026 at 18:00, 1 day 2 hours ago

TF1 Q1 2026 results - Press release

View all LES ECHOS COMFI WIRE

News